Spero Therapeutics
184 articles about Spero Therapeutics
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb. 28, 2020
2/28/2020
Spero Therapeutics, Inc. announced that on February 28, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 24,500 shares of its common stock to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.
-
Spero Therapeutics to Present at March Investor Conferences
2/26/2020
Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the following investor conferences in March 2020:
-
Spero Therapeutics Announces Commencement of Rights Offering
2/11/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today commenced its previously announced rights offering to raise gross proceeds of $30.0 million (the “Rights Offering”).
-
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
2/5/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option for additional committed funding pursuant to its existing contract with Spero.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/31/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that on January 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 6,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Announces Proposed Rights Offering$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020
1/30/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced its intent to raise $30.0 million through a fully backstopped rights offering.
-
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
1/13/2020
First indication of human safety and pharmacokinetic profiles for SPR206 supports advancement of program to clinical pharmacology studies planned to initiate in the second half of 2020
-
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
12/4/2019
First indication of human safety and PK profiles for SPR720 supports
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 29, 2019
11/29/2019
Spero Therapeutics, Inc. announced that on November 29, 2019 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics to Host Key Opinion Leader Symposium in December 2019
11/26/2019
Presentations will highlight the potential for oral SPR994 to change the treatment landscape in cUTI and the opportunity for oral SPR720 in NTM
-
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline ReviewSPR994 pivotal Phase 3 cUTI trial actively enrolling with data expected in the third quarter of 2020
11/4/2019
Spero Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2019 and provided a pipeline review.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on October 31, 2019
10/31/2019
Spero Therapeutics, Inc. announced that on October 31, 2019 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 25,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc.
-
Novo Holdings REPAIR Impact Fund Invests USD 10 million in Curza and Spero
7/23/2019
The Fund has now invested a total of USD 30 million in six companies
-
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
-
Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
6/20/2019
Spero Therapeutics, Inc. announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis, an indication that is designated as a critical concern by the World Health Organization.
-
Spero Therapeutics and the Gates Medical Research Institute Collaborate on Tuberculosis Treatment
6/20/2019
There are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. If successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic. -
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
3/14/2019
Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19
-
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of DirectorsSpero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage
8/14/2018
Spero Therapeutics, Inc. announced the appointment of John C. Pottage, Jr., M.D. to its Board of Directors, effective immediately prior to the next regularly scheduled meeting of the Board of Directors on September 21, 2018.
-
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
8/9/2018
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-end
-
Shares of Cambridge, Mass.-based Spero Therapeutics are climbing this morning after the company announced it secured up to $54 million from the government to support its development of SPR944 as a potential treatment against drug-resistant infections.